AbbVie vs Visa: Founders, CEOs and History
AbbVie was founded in 2013 by Abbott Laboratories (spin-off origin) and is led by Robert A. Michael. Visa was founded in 1958 by Dee Hock and is led by Ryan McInerney.
Company facts
Founders
AbbVie
Abbott Laboratories (spin-off origin)
Abbott Laboratories was AbbVie's corporate predecessor. AbbVie's official launch materials describe the company as formed in 2013 following separation from Abbott. Richard A.
Visa
Dee Hock
Dee Hock (1929-2022) was the founding CEO of National BankAmericard Inc., the bank-owned company that took over the BankAmericard licensing system from Bank of America in 1970 and adopted the Visa name in 1976.
CEOs and their tenures
AbbVie
- Richard A. Gonzalez2013–2024
Founding Chairman and Chief Executive Officer
Served as AbbVie's chief executive officer from its formation in 2013 through June 2024 and as executive chairman through June 2025.
Source - Robert A. Michael2024–present
Chairman and Chief Executive Officer
Became chief executive officer on July 1, 2024 and chairman on July 1, 2025. He previously led finance, commercial operations, and corporate strategy roles at AbbVie.
Source
Visa
- Alfred F. Kelly Jr.2016–2023
Chief Executive Officer
Serving as CEO from 2016 to 2023, he heavily modernized the massive legacy network, aggressively integrating fintechs and preparing the network to process highly complex cryptocurrency transactions.
Source - Ryan McInerney2023–present
Chief Executive Officer
McInerney joined Visa in 2013 as president after senior roles at JPMorgan Chase and became chief executive on February 1, 2023, succeeding Alfred F. Kelly Jr.
Source
Timeline: AbbVie and Visa side by side
1958Visa
BankAmericard launched
Bank of America launched BankAmericard, the direct predecessor to Visa.
1976Visa
Visa name adopted
The network adopted the Visa name to support international acceptance and brand consistency.
2008Visa
Visa IPO
Visa became a public company, changing the economics from a bank association structure to a shareholder-owned company.
2013AbbVie
AbbVie Launches as an Independent Company
AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.
2015AbbVie
Pharmacyclics Acquisition Completed
AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.
2016Visa
Alfred F. Kelly Jr. becomes CEO
Alfred F. Kelly Jr. became CEO of Visa in 2016. Chief executive of Visa from December 2016 to January 2023, when Ryan McInerney succeeded him; Kelly then served as executive chairman.
2019AbbVie
Skyrizi Receives Initial U.S. Approval
The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.
2019AbbVie
Rinvoq Receives Initial U.S. Approval
The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.
2020AbbVie
Allergan Acquisition Completed
AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.
2020Visa
Acquired Plaid (abandoned)
Visa acquired Plaid (abandoned) for $5.3 billion. Visa agreed in January 2020 to buy US data-connectivity fintech Plaid for USD 5.3 billion.
2022Visa
Tink acquisition
Visa completed its purchase of Stockholm-based open banking platform Tink in March 2022.
2023AbbVie
U.S. Humira Biosimilar Competition Begins
Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.
2023Visa
Ryan McInerney becomes CEO
Ryan McInerney became Visa's CEO after serving as president.
2024AbbVie
ImmunoGen Acquisition Completed
AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.
2024AbbVie
Robert A. Michael Becomes CEO
Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.
2024AbbVie
Cerevel Therapeutics Acquisition Completed
AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.
2025AbbVie
Robert A. Michael Becomes Chairman
Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.
2025AbbVie
FY2025 Revenue Reaches $61.160 Billion
AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.
2025Visa
Revenue reaches $40.0B
Visa reported $40.0 billion in fiscal 2025 net revenue.
2026AbbVie
Q1 2026 Revenue Reaches $15.002 Billion
AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.
Acquisitions
AbbVie
- ImmunoGen, Inc.2024$10.1B
- Cerevel Therapeutics2024$8.7B
- Allergan plc2020$63B
- Pharmacyclics, Inc.2015$21B
Questions about AbbVie vs Visa
Who is the CEO of AbbVie Inc. and Visa Inc.?
AbbVie Inc. is led by Robert A. Michael and Visa Inc. is led by Ryan McInerney. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was AbbVie Inc. founded vs Visa Inc.?
Visa Inc. was founded in 1958 — 55 years before AbbVie Inc., which was founded in 2013. Visa Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AbbVie Inc..
How many employees does AbbVie Inc. have compared to Visa Inc.?
AbbVie Inc. employs approximately 57,000 people, while Visa Inc. employs approximately 34,100. AbbVie Inc. has the larger workforce at 57,000 employees, compared to Visa Inc.'s 34,100. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are AbbVie Inc. and Visa Inc. headquartered?
Both AbbVie Inc. and Visa Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded AbbVie Inc. and Visa Inc.?
AbbVie Inc. was founded by Abbott Laboratories (spin-off origin). Visa Inc. was founded by Dee Hock.
Which company has a longer operating history — AbbVie Inc. or Visa Inc.?
Visa Inc. has been operating for approximately 68 years, making it the more established of the two companies. AbbVie Inc. has been in operation for around 13 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Visa overview